Avicanna Sponsors Innovative Clinical Research
Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is making headlines as it embarks on an exciting journey in the realm of medical cannabis. The company has recently entered a Sponsored Research Agreement to activate a significant clinical trial focusing on the efficacy of oral cannabis extracts in alleviating osteoarthritic pain.
Overview of the Clinical Study
This study, titled “The Effectiveness of Oral Cannabis Extracts for Osteoarthritic Pain,” is driven by the expertise of Dr. Hance Clarke, the medical director of the Pain Research Unit. Dr. Clarke is at the forefront of this initiative and is set to lead the trial, expected to initiate in the Fall of 2025.
Primary Objective
The primary goal of this randomized controlled trial (RCT) is to evaluate the feasibility of using oral cannabinoids to enhance pain management in patients suffering from hip and knee osteoarthritis. The study aims to determine aspects such as patient participation, adherence to protocols, and the integrity of the collected data, all of which are critical to the planning of future definitive trials.
Funding and Support
This clinical research is supported by a grant from the Canadian Institutes of Health Research (CIHR), showcasing the commitment to exploring innovative treatments within the framework of health research. Avicanna's involvement is crucial as it supplies proprietary CBD and THC capsules manufactured under Good Manufacturing Practices (GMP), which are essential for the trial.
About Avicanna: A Commitment to Health and Wellness
Avicanna stands as a pioneering biopharmaceutical company dedicated to advancing cannabinoid-based products. With a strong international presence, the firm specializes in the research, manufacturing, and commercialization of these products aimed at the medical and pharmaceutical markets.
Comprehensive Product Offerings
Avicanna's robust portfolio includes a diverse range of products under their RHO Phyto™ brand, which encompasses oral, sublingual, topical, and transdermal solutions. Each product is carefully crafted with various cannabinoid ratios, supported by ongoing education for both patients and healthcare professionals. RHO Phyto™ is currently well-established across Canada and is steadily expanding into new international markets.
Integrated Medical Care through MyMedi.ca
In addition to product development, Avicanna operates the MyMedi.ca platform, designed to enhance the experience for medical cannabis patients. This platform, run by Northern Green Canada Inc., features a broad array of products complemented by pharmacist-led patient support programs. MyMedi.ca also caters to specific groups, such as veterans, ensuring that unique patient needs are met efficiently.
Innovative Pharmaceutical Pipeline
Avicanna's pharmaceutical pipeline showcases a range of proprietary candidates specifically formulated to address various medical challenges, including dermatology, chronic pain, and neurological disorders. The emphasis on scientific innovation and integration positions the company as a leader in cannabinoid research.
Active Pharmaceutical Ingredients
The company's subsidiary, Santa Marta Golden Hemp SAS (SMGH), plays a vital role in supplying high-quality CBD, THC, and CBG to Avicanna's partners worldwide. This vertical integration ensures that Avicanna maintains reliable access to necessary components for their medical and retail products, enhancing the credibility of their offerings across global markets.
Conclusion
Avicanna Inc. is not just a player in the modern biopharmaceutical landscape but a trailblazer paving the way for new advancements in cannabinoid research and product development. As the company embarks on this new clinical study, the potential benefits for patients dealing with osteoarthritis pain could be transformative, showcasing Avicanna’s ongoing commitment to innovation and healthcare improvement.
Frequently Asked Questions
What clinical study is Avicanna sponsoring?
Avicanna is sponsoring an RCT to assess the effectiveness of oral cannabis extracts for osteoarthritic pain.
Who is leading the clinical study?
The clinical study is led by Dr. Hance Clarke, a prominent medical director in pain research.
What are the primary objectives of the study?
The primary aim is to evaluate the feasibility of using oral cannabinoids to manage pain in osteoarthritis patients.
How is the study funded?
The clinical study is financially supported by a grant from the Canadian Institutes of Health Research (CIHR).
What other initiatives does Avicanna have?
Avicanna offers a range of products and services, including a medical cannabis care platform, pharmaceutical development, and active pharmaceutical ingredients through its subsidiary, SMGH.
